Chi-Med shares slide 19% on fruquintinib failure

16 November 2018

Hutchison China MediTech (AIM: HCM) lost 19% of its market value on Friday following the Phase III failure of a drug that has just been approved to treat advanced colorectal cancer.

The company, known as Chi-Med, received approval from the National Medical Products Administration of China to market fruquintinib in this indication in September, and it is about to launch the product in collaboration with partner Eli Lilly (NYSE: LLY).

Chi-Med has billed itself as a leader of the Chinese pharma charge and hailed fruquintinib as the first China-discovered and developed pharmaceutical for a mainstream oncology indication to be unconditionally approved in the Asian country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK